Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ETCF | ISIN: CNE100006624 | Ticker-Symbol: R9Z
Frankfurt
27.06.25 | 09:59
1,140 Euro
-6,56 % -0,080
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC Chart 1 Jahr
5-Tage-Chart
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,1601,25011:23

Aktuelle News zur IMMUNEONCO BIOPHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoIMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR THE CLINICAL TRIAL OF IMC-003/IMM724
IMMUNEONCO BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln
16.06.IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTIONS - REDEMPTION AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS-
09.06.IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF MEDICAL OFFICER1
28.05.IMMUNEONCO-B (01541): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS3
28.05.IMMUNEONCO-B (01541): I. POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2025; II. APPOINTMENT OF DIRECTOR-
27.05.IMMUNEONCO-B (01541): SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS2
23.05.Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago1
22.05.Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ('2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 ...220Phase 3 trial of '2510 in combination with chemotherapy in first-line NSCLC anticipated to start in mid-2026 in China, subject to regulatory discussions Monotherapy US dose optimization Phase 1b/2...
► Artikel lesen
22.05.IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIALS OF IMM2510/AXN-2510 IN COMBINATION WITH CHEMOTHERAPY IN FIRST-LINE NSCLC-
14.05.IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN-
14.05.IMMUNEONCO-B (01541): INSIDE INFORMATION - COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY1
07.05.IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FURTHER PAYMENT RECEIVED UNDER THE LICENSE AND COLLABORATION AGREEMENT WITH AXION BIO FOR IMM2510 (PALVERAFUSP) ...1
06.05.IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF BUSINESS OFFICER1
30.04.IMMUNEONCO-B (01541): PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 28, 2025-
30.04.IMMUNEONCO-B (01541): NOTICE OF THE ANNUAL GENERAL MEETING-
30.04.IMMUNEONCO-B (01541): CIRCULAR OF THE 2024 ANNUAL GENERAL MEETING1
25.04.IMMUNEONCO-B (01541): ANNUAL REPORT 20241
24.04.IMMUNEONCO-B (01541): NSIDE INFORMATION - THE H SHARE FULL CIRCULATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE2
02.04.IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMC-003/IMM72-
26.03.IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD-
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1